Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER2+ Breast Cancer

Hamann, 2005, Monoclonal antibody-drug conjugates, Expert Opin Ther Patents, 15, 1087, 10.1517/13543776.15.9.1087

Wu, 2005, Arming antibodies: prospects and challenges for immunoconjugates, Nature Biotechnol, 23, 1137, 10.1038/nbt1141

Carter, 2006, Potent antibody therapeutics by design, Nat Rev Immunol, 6, 343, 10.1038/nri1837

Trail, 1999, Monoclonal antibody drug conjugates in the treatment of cancer, Curr Opin Immunol, 11, 584, 10.1016/S0952-7915(99)00012-6

Damle, 2003, Antibody-targeted chemotherapy with immunoconjugates of calicheamicin, Curr Opin Pharmacol, 3, 386, 10.1016/S1471-4892(03)00083-3

Sievers, 2001, Mylotarg: antibody-targeted chemotherapy comes of age, Curr Opin Oncol, 13, 522, 10.1097/00001622-200111000-00016

Lambert, 2005, Drug-conjugated monoclonal antibodies for the treatment of cancer, Curr Opin Pharmacol, 5, 543, 10.1016/j.coph.2005.04.017

Polakis, 2005, Arming antibodies for cancer therapy, Curr Opin Pharmacol, 5, 382, 10.1016/j.coph.2005.04.008

Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106

Xie, 2006, In vivo behaviour of antibody-drug conjugates for the targeted treatment of cancer, Expert Opin Biol Ther, 6, 281, 10.1517/14712598.6.3.281

Chari, 2008, Targeting cancer therapy: conferring specificity to cytotoxic drugs, Acc Chem Res, 41, 98, 10.1021/ar700108g

Yarden, 2001, Untangling the ErbB signalling network, Nat Rev Mol Cell Biol, 2, 127, 10.1038/35052073

Press, 1990, Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues, Oncogene, 5, 953

Slamon, 1989, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 244, 707, 10.1126/science.2470152

Press, 1993, Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease, Cancer Res, 53, 4960

Ravdin, 1995, The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers—a review, Gene, 159, 19, 10.1016/0378-1119(94)00866-Q

Junttila, 2009, Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941, Cancer Cell, 15, 429, 10.1016/j.ccr.2009.03.020

Albanell, 2003, Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4, Adv Exp Med Biol, 532, 253, 10.1007/978-1-4615-0081-0_21

Molina, 2001, Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells, Cancer Res, 61, 4744

Izumi, 2002, Tumour biology: herceptin acts as an anti-angiogenic cocktail, Nature, 416, 279, 10.1038/416279b

Lewis, 1993, Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies, Cancer Immunol Immunother, 37, 255, 10.1007/BF01518520

Cooley, 1999, Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu, Exp Hematol, 27, 1533, 10.1016/S0301-472X(99)00089-2

Clynes, 2000, Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets, Nat Med, 6, 443, 10.1038/74704

Mohsin, 2005, Neoadjuvant trastuzumab induces apoptosis in primary breast cancers, J Clin Oncol, 23, 2460, 10.1200/JCO.2005.00.661

Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, 783, 10.1056/NEJM200103153441101

Marty, 2005, Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group, J Clin Oncol, 23, 4265, 10.1200/JCO.2005.04.173

Romond, 2005, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N Engl J Med, 353, 1673, 10.1056/NEJMoa052122

Slamon D, Eiermann W, Robert N, et al. BCIRG 006 phase III trial comparing AC→T with AC→TH and with TCH in the adjuvant treatment of HER2-amplified early breast cancer patients: third planned efficacy analysis. Presented at the 32nd Annual San Antonio Breast Cancer Symposium, December 9-13, 2009, abstract 62.

Smith, 2007, Two-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial, Lancet, 369, 29, 10.1016/S0140-6736(07)60028-2

Esteva, 2002, Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer, J Clin Oncol, 20, 1800, 10.1200/JCO.2002.07.058

Spector, 2005, Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies, J Clin Oncol, 23, 2502, 10.1200/JCO.2005.12.157

Tripathy, 2004, Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression, J Clin Oncol, 22, 1063, 10.1200/JCO.2004.06.557

Burstein, 2003, Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study, J Clin Oncol, 21, 46, 10.1200/JCO.2003.03.124

Mass, 2005, Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab, Clin Breast Cancer, 6, 240, 10.3816/CBC.2005.n.026

Lu, 2001, Insulin-like growth factor-1 receptor signalling and resistance to trastuzumab (herceptin), J Natl Cancer Inst, 93, 1852, 10.1093/jnci/93.24.1852

Berns, 2007, A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer, Cancer Cell, 12, 395, 10.1016/j.ccr.2007.08.030

Nagata, 2004, PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients, Cancer Cell, 6, 117, 10.1016/j.ccr.2004.06.022

Ritter, 2007, Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network, Clin Cancer Res, 13, 4909, 10.1158/1078-0432.CCR-07-0701

Dua, 2010, EGFR over-expression and activation in high HER2, ER negative breast cancer cell lines induces trastuzumab resistance, Breast Cancer Res Treat, 122, 685, 10.1007/s10549-009-0592-x

Nahta, 2004, P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells, Cancer Res, 64, 3981, 10.1158/0008-5472.CAN-03-3900

Scaltriti, 2007, Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer, J Natl Cancer Inst, 99, 628, 10.1093/jnci/djk134

Molina, 2002, NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer, Clin Cancer Res, 8, 347

Saez, 2006, p95HER-2 predicts worse outcome in patients with HER-2 positive breast cancer, Clin Cancer Res, 12, 424, 10.1158/1078-0432.CCR-05-1807

Junttila, 2010, Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer, Breast Cancer Res Treat

Lewis Phillips, 2008, Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate, Cancer Res, 68, 9280, 10.1158/0008-5472.CAN-08-1776

Austin, 2004, Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin, Mol Biol Cell, 15, 5268, 10.1091/mbc.E04-07-0591

Shen, 1986, Targeting, internalization, and cytotoxicity of methotrexate-monoclonal anti-stage-specific embryonic antigen-1 antibody conjugates in cultured F-9 teratocarcinoma cells, Cancer Res, 46, 3912

Johnson, 1987, Antitumor xenograft activity with a conjugate of a vinca derivative and the squamous carcinoma–reactive monoclonal antibody PF1/D, Cancer Res, 47, 3118

Dillman, 1988, Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug, Cancer Res, 48, 6097

Allen, 2002, Ligand-targeted therapeutics in anticancer therapy, Nat Rev Cancer, 2, 750, 10.1038/nrc903

Sparano, 2000, Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials, Clin Breast Cancer, 1, 32, 10.3816/CBC.2000.n.002

Remillard, 1975, Anti-mitotic activity of the potent tubulin inhibitor maytansine, Science, 189, 1002, 10.1126/science.1241159

Blum, 1978, Maytansine: a phase I study of an ansa macrolide with antitumor activity, Cancer Treat Rep, 62, 435

Cabanillas, 1978, Phase I study of maytansine using a 3-day schedule, Cancer Treat Rep, 62, 425

Chabner, 1978, Initial clinical trials of maytansine, an antitumor plant alkaloid, Cancer Treat Rep, 62, 429

Eagan, 1978, Early clinical study of an intermittent schedule for maytansine (NSC-153858): brief communication, J Natl Cancer Inst, 60, 93, 10.1093/jnci/60.1.93

Issell, 1978, Maytansine, Cancer Treat Rev, 5, 199, 10.1016/S0305-7372(78)80014-0

Cassady, 2004, Recent developments in the maytansinoid antitumor agents, Chem Pharm Bull (Tokyo), 52, 1, 10.1248/cpb.52.1

Blattler, 2001, Drugs to enhance the therapeutic potency of anticancer antibodies: antibody-drug conjugates as tumor-activated prodrugs, 317

Goldmacher, 2002, Immunotoxins and antibody-drug conjugates for cancer treatment, 291

Kovtun, 2006, Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen, Cancer Res, 66, 3214, 10.1158/0008-5472.CAN-05-3973

Kung, 2006, Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-cd30-auristatin conjugates, J Biol Chem, 281, 10540, 10.1074/jbc.M510026200

Doronina, 2002, Development of potent monoclonal antibody auristatin conjugates for cancer therapy, Nature Biotechnol, 45, 4336

Krop, 2010, Phase I study of trastuzumab-DM1, a HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer, J Clin Oncol, 28, 2698, 10.1200/JCO.2009.26.2071

Beeram, 2007, A phase I study of trastuzumab-DM1, a first-in-class HER-2 antibody-drug conjugate (ADC) in patients with HER2+ metastatic breast cancer, J Clin Oncol, 25, 42s

Tolcher, 2003, Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study, J Clin Oncol, 21, 211, 10.1200/JCO.2003.05.137

Burris, 2011, Phase II study of the antibody drug conjugate trastuzumab-dm1 (TDM1) for the treatment of HER2-positive breast cancer following prior HER2-directed therapy, J Clin Oncol, 29, 398, 10.1200/JCO.2010.29.5865

Krop I, Lorusso P, Miller KD, et al. A phase II study of trastuzumab-DM1 (TDM1), a novel HER2 antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer who were previously treated with an anthracycline, a taxane, capecitabine, lapatinib, and trastuzumab. Presented at the European Society for Medical Oncology October 10, 2010, Milan, Italy, abstract 277O.

Krop, 2009, Quantitative assessment of HER2 status and correlation with efficacy for patients (pts) with metastatic breast cancer (MBC) in a phase ii study of trastuzumab-DM1 (T-DM1), J Clin Oncol, 27, 15s, 10.1200/jco.2009.27.15_suppl.1003

LoRusso, 2010, Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy, J Clin Oncol, 28, 15s

Perez, 2010, Ann Oncol, 21, viii2